Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC

Study acronym: OMET
StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Jul 2026 → Dec 2026
See other at-risk trials from Groupe Oncologie Radiotherapie Tete et Cou

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 2026 to Dec 2026
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: details revised at 1 of 5 entries
  2. 2 versions Re-verified since Jul 3, 2024, no change to tracked fieldsv9-v10
  3. Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Aug 2026 to Jul 2026
    • Site details revised
    v8
  4. Primary completion date: Jul 2021 to Jul 2026
    • Study completion date: Dec 2021 to Aug 2026
    v7
  5. Primary completion date: Jul 2020 to Jul 2021
    • Study completion date: Dec 2020 to Dec 2021
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Primary completion date: Feb 2020 to Jul 2020
    • Study completion date: Feb 2020 to Dec 2020
    v5
  2. Primary completion date: Sep 2020 to Feb 2020
    • Study completion date: Oct 2021 to Feb 2020
    • Start date: Sep 2016 to Sep 21, 2015
    v4
  3. 2 versions Re-verified since Dec 11, 2017, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to evaluate the rate of living patients at 1 year with a quality of life criteria (no decrease) and reduced toxicities. This criteria will be compared in both groups., A cost effectiveness study is scheduled also.
Trial Details
NCT Number NCT03070366
Lead Sponsor Groupe Oncologie Radiotherapie Tete et Cou
Conditions
(from sponsor)		 Head and Neck Squamous Cell Carcinoma
Related terms Squamous Cell Carcinoma of Head and Neck
Enrollment 78 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov